Efficacy and safety of different doses of Rosuvastatin calcium in treating elderly patients with coronary heart disease complicated with hyperlipidemia
Lijuan Guo, Lu Fang, Xiaoxia Hu, Yong Li
Abstract
Lijuan Guo, Lu Fang, Xiaoxia Hu, Yong Li
Abstract
Objective To investigate the efficacy and safety of different doses of Rosuvastatin calcium in treating elderly patients with coronary heart disease complicated with hyperlipidemia. Methods A total of 130 patients with coronary heart disease in combination with hyperlipidemia admitted into our hospital from January 2015 to December 2017 were enrolled.They were randomly divided into the control group(with Rosuvastatin calcium 10 mg per day, n=65)and the study group(with Rosuvastatin calcium 20 mg per day, n=65). Clinical efficacy, changes of blood lipid levels and adverse reactions after treatment were compared between the two groups. Results In the study group, 25 cases had obvious effects, 35 cases had effects and 5 cases had no effect.In the control group, 21 cases with obvious effects, 31 cases with effects and 13 cases without effect were found.The total effective rates were 92.3% in the study group and 80.0% in control group(χ2=4.127, P=0.042). The blood levels of total cholesterol(TC), triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)in the study group were decreased in post-vs.pre-treatment, and were lower in treatment group than in control group(all P=0.000). Nausea and vomiting in 1 case, and muscle ache in 1 case were found in the control group.In the study group, 2 cases of nausea and vomiting, 2 cases of skin rash, 1 case of muscle ache, and 2 cases of joint ache were found.The incidences of adverse reactions were 10.8% and 3.1% in the study and control group respectively, with no significant difference between the two groups(χ2=2.984, P=0.084). Conclusions The high-dose of Rosuvastatin calcium(20 mg daily)has significant clinical efficacy and improve the blood lipid levels in elderly patients with coronary heart disease complicated with hyperlipidemia, with no significant difference in incidence of adverse reactions between 10 mg daily versus 20 mg daily Rosuvastatin calcium. Key words: Coronary disease; Hyperlipidemias
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the efficacy and safety of different doses of Rosuvastatin calcium in treating elderly patients with coronary heart disease complicated with hyperlipidemia. Methods A total of 130 patients with coronary heart disease in combination with hyperlipidemia admitted into our hospital from January 2015 to December 2017 were enrolled.They were randomly divided into the control group(with Rosuvastatin calcium 10 mg per day, n=65)and the study group(with Rosuvastatin calcium 20 mg per day, n=65). Clinical efficacy, changes of blood lipid levels and adverse reactions after treatment were compared between the two groups. Results In the study group, 25 cases had obvious effects, 35 cases had effects and 5 cases had no effect.In the control group, 21 cases with obvious effects, 31 cases with effects and 13 cases without effect were found.The total effective rates were 92.3% in the study group and 80.0% in control group(χ2=4.127, P=0.042). The blood levels of total cholesterol(TC), triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)in the study group were decreased in post-vs.pre-treatment, and were lower in treatment group than in control group(all P=0.000). Nausea and vomiting in 1 case, and muscle ache in 1 case were found in the control group.In the study group, 2 cases of nausea and vomiting, 2 cases of skin rash, 1 case of muscle ache, and 2 cases of joint ache were found.The incidences of adverse reactions were 10.8% and 3.1% in the study and control group respectively, with no significant difference between the two groups(χ2=2.984, P=0.084). Conclusions The high-dose of Rosuvastatin calcium(20 mg daily)has significant clinical efficacy and improve the blood lipid levels in elderly patients with coronary heart disease complicated with hyperlipidemia, with no significant difference in incidence of adverse reactions between 10 mg daily versus 20 mg daily Rosuvastatin calcium. Key words: Coronary disease; Hyperlipidemias
Key concepts: Medicine, Hyperlipidemia, Nausea, Rosuvastatin, Adverse effect, Vomiting, Internal medicine, Gastroenterology